Literature DB >> 15985363

Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation.

Yu Chul Kim1, Ae Kyung Lee, Joo Hyun Lee, Inchul Lee, Duk Chul Lee, So Hee Kim, Sang Geon Kim, Myung Gull Lee.   

Abstract

Pharmacokinetic parameters of theophylline and one of its metabolites, 1,3-dimethyluric acid (1,3-DMU), were compared after intravenous and oral administration of aminophylline, 5mg/kg as theophylline, to diabetes mellitus rats induced by alloxan (DMIA) or streptozotocin (DMIS), and their respective control rats. In DMIA and DMIS rats, expression of CYP1A2 and 2E1 increased approximately three times. Theophylline was metabolized to 1,3-DMU by CYP1A2 and 2E1 in rats. Hence, it was expected that formation of 1,3-DMU increased in DMIA or DMIS rats. This was proven by the following results. First, after intravenous administration of theophylline, the AUC of 1,3-DMU was significantly greater in DMIA (110% increase) or DMIS (47.4% increase) rats. Second, the AUC of theophylline was significantly smaller in DMIA (26.1% decrease) or DMIS (30.1% decrease) rats because of significantly faster time-averaged total body clearance in DMIA (34.8% increase) or DMIS (42.7% increase) rats. Third, based on in vitro hepatic microsomal studies, intrinsic 1,3-DMU formation clearances were significantly faster in DMIA (20.4% increase) or DMIS (30.7% increase) rats than respective control rats. Similar results (AUC values of theophylline and 1,3-DMU) were also obtained after oral administration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15985363     DOI: 10.1016/j.ejps.2005.05.004

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  15 in total

1.  Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1 and 3A1/2 for the metabolism of metformin.

Authors:  Y H Choi; M G Lee
Journal:  Br J Pharmacol       Date:  2006-08-29       Impact factor: 8.739

2.  Effects of Escherichia coli lipopolysaccharide on telithromycin pharmacokinetics in rats: inhibition of metabolism via CYP3A.

Authors:  Joo H Lee; Yu K Cho; Young S Jung; Young C Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

3.  Pharmacokinetics of itraconazole in diabetic rats.

Authors:  Unji Lee; Young H Choi; So H Kim; Byung K Lee
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

4.  The effect of streptozotocin and alloxan on the mRNA expression of rat hepatic transporters in vivo.

Authors:  Ting Zhai; Junjun Wang; Lijuan Sun; Yong Chen
Journal:  AAPS PharmSciTech       Date:  2014-12-31       Impact factor: 3.246

Review 5.  Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.

Authors:  Enoch Cobbina; Fatemeh Akhlaghi
Journal:  Drug Metab Rev       Date:  2017-03-17       Impact factor: 4.518

6.  Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin.

Authors:  Joo H Lee; Myung G Lee
Journal:  Pharm Res       Date:  2008-05-14       Impact factor: 4.200

7.  Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis.

Authors:  C Y Ahn; S K Bae; S H Bae; T Kim; Y S Jung; Y C Kim; M G Lee; W G Shin
Journal:  Br J Pharmacol       Date:  2009-03       Impact factor: 8.739

Review 8.  Strategies for preclinical pharmacokinetic investigation in streptozotocin-induced diabetes mellitus (DMIS) and alloxan-induced diabetes mellitus (DMIA) rat models: case studies and perspectives.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-03-06       Impact factor: 2.441

Review 9.  Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1.

Authors:  P S S Rao; Narasimha M Midde; Duane D Miller; Subhash Chauhan; Anil Kumar; Santosh Kumar
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731

10.  Diabetes mellitus aggravates ranolazine-induced ECG changes in rats.

Authors:  Habibeh Mashayekhi-Sardoo; Amir Hooshang Mohammadpour; Soghra Mehri; Hossein Kamali; Amirhossein Sahebkar; Mohsen Imenshahidi
Journal:  J Interv Card Electrophysiol       Date:  2021-06-21       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.